It's been exactly one year since the "Expanded Access" study began and 8 months sine we last received an update on the website.
Thos following closely along remember the previous "Expanded Access" trial named "Euphoria" running from the end of the phase III Euphrates trial ( June 2016 ) until April 2018 when it was "retro-fitted" as a CV19 application. The key to the study below is the ability to use beyond the 2 filter limit that has potantially hampered the efficacy of other PMX studies. Given we now have the trial experience, real world data of 300K patients treated, and of course the FDA approved EAA diagnostic to screen and monitor, it would seem that upping the dosage and analyzing the results would be a useful medical endeavor as it pertains to severe sepsis and specifically "endotoxemic septic shock". GLTA
Trial record 7 of 10 for: toraymyxin
Evaluating the Use of Polymyxin B Cartridge Hemoperfusion for Patients With Septic Shock and COVID 19
 | The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT04352985 |
Expanded Access Status : Available First Posted : April 20, 2020 Last Update Posted : August 28, 2020 |